Evidence map›Paper›PMID 25909320›Full record

Trial reportPloS one2015

Randomized controlled trial of a mobile phone intervention for improving adherence to naltrexone for alcohol use disorders.

Susan A Stoner, Pamela B Arenella, Christian S Hendershot

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01349985 (SBIR-PhaseII, "Adaptive Goal-Directed Adherence Tracking and Enhancement"), which is not on this map. Cited by 24 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01349985 phase2completednot on this map

SBIR-PhaseII, "Adaptive Goal-Directed Adherence Tracking and Enhancement"

TypeinterventionalSponsorTalaria, IncRan2011 to 2013Enrolled136ConditionsAlcohol AbuseArmsAGATE, SASED
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The Effectiveness of Mobile Phone-Based Text Messaging to Intervene with Problem Drinking in Youth and Younger Adult Population: A Meta-Analysis.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Review
  8. Hypocretin receptor 1 blockade early in abstinence prevents incubation of cocaine seeking and normalizes dopamine transmission.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Predictors of Daily Adherence to Naltrexone for Alcohol Use Disorder Treatment During a Mobile Health Intervention.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2018
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Susan A StonerAlcohol and Drug Abuse Institute, University of Washington, Seattle, Washington, United States of America.
Pamela B ArenellaDepartment of Psychiatry, University of New Mexico, Albuquerque, New Mexico, United States of America.
Christian S HendershotCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Psychology, University of Toronto, Toronto, Ontario, Canada; The Mind Research Network and Lovelace Biomedical and Environmental Research Institute, Albuquerque, New Mexico, United States of America.

Funding

NICHD NIH HHS HHSN275201000011CPHS HHS HHSN275201000011C
6 · The paper itself

Abstract

backgroundNaltrexone is a front-line treatment for alcohol use disorders, but its efficacy is limited by poor medication adherence. This randomized controlled trial evaluated whether a mobile health intervention could improve naltrexone adherence.

methodsTreatment-seeking participants with an alcohol use disorder (N = 76) were randomized to intervention and control conditions. All participants received naltrexone (50 mg/day) with a medication event monitoring system (MEMS) and a prepaid smartphone, and received a daily text message querying medication side effects, alcohol use, and craving. Those in the intervention arm received additional medication reminders and adherence assessment via text message.

resultsThe primary outcome, proportion of participants with adequate adherence (defined as ≥80% of prescribed doses taken through Week 8), did not differ between groups in intent-to-treat analyses (p = .34). Mean adherence at study midpoint (Week 4) was 83% in the intervention condition and 77% in the control condition (p = .35). Survival analysis found that the intervention group sustained adequate adherence significantly longer (M = 19 days [95% CI = 0.0-44.0]) than those in the control group (M = 3 days [95% CI = 0.0-8.1]) during the first month of treatment (p = .04). Medication adherence did not predict drinking outcomes.

conclusionsThese results suggest that in the context of daily monitoring and assessment via cell phone, additional text message reminders do not further improve medication adherence. Although this initial trial does not provide support for the efficacy of text messaging to improve adherence to pharmacotherapy for alcohol use disorders, additional trials with larger samples and alternate designs are warranted.

trial registrationClinicalTrials.gov: NCT01349985.

Indexed as

Cell PhoneMedication AdherenceAdultAlcohol-Related DisordersFemaleHumansMaleMiddle AgedNaltrexoneNarcotic AntagonistsPublic Health SurveillanceRisk FactorsSurveys and QuestionnairesText MessagingTreatment OutcomeYoung AdultNaltrexoneNarcotic Antagonists

Identifiers

PMID25909320
PMCPMC4409303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.